Seamless phase II/III/IIIb clinical trial designs with different endpoints for different phases

被引：2
|
作者：
Quan, Hui [1 ]
Luo, Xiaodong [1 ]
Zhou, Tianyue [1 ]
Zhao, Peng-Liang [1 ]
机构：
[1] Sanofi, Biostat & Programming, 55C-335A,55 Corp Dr, Bridgewater, MA 08807 USA
来源：
COMMUNICATIONS IN STATISTICS-THEORY AND METHODS | 2020年 / 49卷 / 22期
关键词：
Multiplicity adjustment; combination test; conditional power; estimation of treatment effect; TREATMENT SELECTION; SEQUENTIAL DESIGNS; INTERIM;
D O I：
10.1080/03610926.2019.1618871
中图分类号：
O21 [概率论与数理统计]; C8 [统计学];
学科分类号：
020208 ; 070103 ; 0714 ;
摘要：
In a seamless phase II/III/IIIb trial, K (K >= 2) doses versus placebo control are evaluated at phase II. Based on phase II results, one dose will be selected for phases III and IIIb. Pre-specified additional numbers of patients will be enrolled into the selected dose and placebo control during phases III and IIIb. Results of the phase III endpoint may be submitted for an early New Drug Application. Final analyses will be conducted for ultimate claims of treatment effects for the selected dose on the phase III and IIIb endpoints. Multiplicity adjustment is performed for the overall type I error rate control.
引用
收藏
页码：5436 / 5454
页数：19
相关论文
共 50 条
  • [1] Seamless phase II/III designs
    Stallard, Nigel
    Todd, Susan
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2011, 20 (06) : 623 - 634
  • [2] Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints
    Sharma, Manish R.
    Karrison, Theodore G.
    Jin, Yuyan
    Bies, Robert R.
    Maitland, Michael L.
    Stadler, Walter M.
    Ratain, Mark J.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (08) : 2309 - 2315
  • [3] VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints
    Sharma, M.
    Karrison, T.
    Maitland, M. L.
    Stadler, W. M.
    Ratain, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Seamless phase II-III adaptive trial design elements for progressive MS: Neurofilament light chain (phase II/interim endpoint), phase III endpoints and patient populations
    Lieberman, D. R.
    Giovannoni, G.
    Cafferty, F.
    Bianchi, L.
    Gnanapavan, S.
    Marta, M.
    Altmann, D. R.
    Kapoor, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 600 - 600
  • [5] Adaptive seamless phase II/III designs - Background, operational aspects, and examples
    Maca, Jeff
    Bhattacharya, Suman
    Dragalin, Vladimir
    Gallo, Paul
    Krams, Michael
    [J]. DRUG INFORMATION JOURNAL, 2006, 40 (04): : 463 - 473
  • [6] Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples
    Jeff Maca
    Sumon Bhattacharya
    Vladimir Dragalin
    Paul Gallo
    Michael Krams
    [J]. Drug information journal : DIJ / Drug Information Association, 2006, 40 : 463 - 473
  • [7] Seamless phase II/III trial design with survival and PRO endpoints for treatment selection: Case study of RTOG 1216.
    Rosenthal, David Ira
    Zhang, Qiang
    Kies, Merrill S.
    Minh-Tam Truong
    Jordan, Richard
    Harari, Paul A.
    Quynh-Thu Le
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] VALUATION OF THE DIFFERENT PHASES OF CLINICAL-TRIAL
    VONEICKSTEDT, KW
    [J]. MUNCHENER MEDIZINISCHE WOCHENSCHRIFT, 1983, 125 : 21 - 25
  • [9] CLINICAL TRIAL DESIGNS WITH REAL WORLD ENDPOINTS
    Margolis, D. J.
    [J]. WOUND REPAIR AND REGENERATION, 2015, 23 (04) : A19 - A19
  • [10] A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints
    Kunz, Cornelia Ursula
    Friede, Tim
    Parsons, Nicholas
    Todd, Susan
    Stallard, Nigel
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2015, 25 (01) : 170 - 189
12345